Michael Mulcahy is the Chief Executive and the Founder of Ascalon; and is the inventor of the company’s innovative technology. After graduation from Rensselaer Polytechnic Institute with a degree in Materials Engineering, Mr. Mulcahy began his professional career with the US Navy as an aircraft carrier pilot line officer. Upon leaving the US Navy after twenty-two years as a Captain, he held Executive positions at Tyco and United Technologies. Building on these experiences, he formed Ascalon to focus on non-toxic, environmentally sustainable technologies that promote human health and well-being.
The origins that guided the idea and creation for Ascalon’s base technology began in the Navy by attempting to solve the challenges to deliver a non-toxic liquid that is universally effective as a decontaminant to mitigate chemical and biological weapon toxins. From that experience, it became clear that there were much larger applications for disinfectants, sanitizers, and cleaning products in substantial and diverse markets that were collectively underserved by inferior performance using toxic, hazardous, and polluting products.
Michael’s research led to the invention and development of a series of products made entirely from botanically-derived and food grade components that out perform all disinfectant products available today. The core of this technology product is distinguished by its unique capability to remove biofilm. By removing the biofilm, the remaining harmful microorganisms are either removed or destroyed in the process.
The target markets served by Ascalon’s technology are: healthcare, food processing, hospitality, institutional hygiene, hospitality, athletics and fitness, schools and universities, health and wellness industry, and consumer products. The aggregated annual sales volume for these market segments exceeds $25 billion globally; $14 billion in US markets. Ascalon’s product portfolio consists of multipurpose cleaning products, hospital grade disinfectants, sterilizers for surfaces and surgical instruments, and wound care applications. Future prototype products now in development include skin healing and rejuvenating applications for healthcare and beauty products market segments.